Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2007

View Archived Issues

Clinical studies of new drugs to treat disorders of reduced GI motility

Novel immunosuppressants disclosed by Sankyo

Recent Tsumura patents impart novel therapeutic agents for diabetic retinopathy

New treatments for musculoskeletal and connective tissue disorders claimed in recent patents

Efficacy and safety of linaclotide acetate in women with constipation-predominant IBS

PSN-GK1: a glucokinase activator with glucose-lowering and insulinotropic activity in vivo

Clinical research reported at the 2007 Society of Biological Psychiatry meeting

New ceramide derivatives beneficial in models of chronic skin inflammatory disease

Dexloxiglumide shows utility for c-IBS in phase III trial

Phase I study under way for ABT-107

Oral calcitonin begins phase III for treatment of osteoarthritis

Nycomed and Micromet to develop anti-GM-CSF antibodies

Marketing agreement signed for PSD-502 for premature ejaculation

U.S. orphan drug designation for Vekacia in vernal keratoconjunctivitis

VaxGen discontinues development of recombinant anthrax vaccine

New site added in phase II trial of atiprimod in advanced carcinoid cancer

Exjade labeling receives new Warning and Adverse Reactions information

New phase II/III trial investigates CDX-110 in glioblastoma multiforme

Exelixis files IND for XL-019

Preterax evaluation closes in ADVANCE diabetes trial

Sanofi-aventis recaps quarterly highlights

CHMP hands down negative opinion for Vectibix in metastatic colorectal cancer

Increlex recommended for approval in E.U.

Novel xanthine oxidase inhibitors for gout emerge from Kissei R&D

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...